CH239111A - Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body. - Google Patents

Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body.

Info

Publication number
CH239111A
CH239111A CH239111DA CH239111A CH 239111 A CH239111 A CH 239111A CH 239111D A CH239111D A CH 239111DA CH 239111 A CH239111 A CH 239111A
Authority
CH
Switzerland
Prior art keywords
organs
animal
human body
production
acetic acid
Prior art date
Application number
Other languages
German (de)
Inventor
Ag Cilag Chemisch Laboratorium
Original Assignee
Cilag Chemisches Ind Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cilag Chemisches Ind Lab Ag filed Critical Cilag Chemisches Ind Lab Ag
Publication of CH239111A publication Critical patent/CH239111A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  



  Verfahren zur Herstellung einer für die   rontgenographische    Darstellung der Organe des tierischen und menschlichen Körpers geeigneten   Eontrastsubstanz.   



   Zur röntgenographischen Darstellung der Organe des tierischen und menschlichen Körpers sind eine Reihe von Salzen der 3,5-Dijod  2-pyridon-N-essigsäure    und der 3, 5-Dijod-4  pyridon-N-essigsäure    verwendet worden. Alle bekannten Salze dieser Säuren haben den Nachteil, daB sie entweder zu wenig wasserlöslich sind, so dass sich damit Lösungen von der zur röntgenographischen Organdarstellung wünschenswerten Konzentration nicht herstellen lassen, oder aber, dass sie bei der Anwendung eine heftige Trombophlebitis verursachen.



   Es wurde nun gefunden, dass die salz  a. rtigen Molekülverbindungen    des   Morpholins    mit   1-Carboxymethyl-3,    5-dijod-pyridonen, nämlich das 3,5-dijod-2-pyridon-N-essigsaure, das 3,5-dijod-4-pyridon-N-essigsaure, das 3,5dijod-6-methyl-2-pyridon-N-essigsaure und das 3, 5-dijod-6-methyl-4-pyridon-N-essigsaure Morpholin eine zur Verwendung als   rönt-      genographisches Kontrastmittel    mehr als ausreichende Löslichkeit in Wasser besitzen, ferner,   dass ihre wässerigenLösungen schmerz-    los injizierbar sind und keine Trombophlebitis erzeugen.



   Gegenstand des Patentes ist ein Verfahren zur Herstellung einer für die röntgenographische Darstellung der Organe des tierischen und menschlichen Körpers geeigneten Kontrastsubstanz, dadurch gekennzeichnet, da,   B man Morpholin und 3,    5-Dijod-4-pyridon  N-essigsäure,    zweckmässig im molekularen Verhältnis 1 : 1 aufeinander einwirken lässt, wobei sich eine salzartige   Molekülverbindung    bildet.



   Zur Herstellung der Molekülverbindung werden beispielsweise   40, 5    g 3,5-Dijod-4-pyri  don-N-essigsäure    und 8,71 g Morpholin in 250   em3 heissem Athanol gelost.    Beim   Erkal-    ten kristallisiert die neue Verbindung in einer Menge von 48 g aus. Das so erhaltene 3,5dijod-4-pyridon-N-essigsaure Morpholin bildet farblose,   perlmutterglänzende Plättchen,    die sich bei   145  C    zu zersetzen beginnen. Es lost sich in Wasser sehr leicht mit neutraler Reaktion und soll als wässerige, zweckmässig   20      0    bis 60 volumprozentige Lösung zu Injektionen verwendet werden.



  



  Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body.



   A number of salts of 3,5-diiodo-2-pyridone-N-acetic acid and 3, 5-diiodo-4-pyridone-N-acetic acid have been used for the radiographic representation of the organs of the animal and human body. All known salts of these acids have the disadvantage that they are either too insoluble in water, so that they cannot be used to produce solutions of the concentration desirable for radiographic organ imaging, or that they cause violent thrombophlebitis when used.



   It has now been found that the salt a. real molecular compounds of morpholine with 1-carboxymethyl-3, 5-diiodopyridones, namely 3,5-diiodo-2-pyridon-N-acetic acid, 3,5-diiodo-4-pyridon-N-acetic acid, the 3rd , 5-diiodo-6-methyl-2-pyridon-N-acetic acid and 3, 5-diiodo-6-methyl-4-pyridon-N-acetic acid morpholine have more than sufficient solubility in water for use as radiographic contrast media, also that their aqueous solutions are painlessly injectable and do not cause thrombophlebitis.



   The subject of the patent is a process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body, characterized in that one is morpholine and 3,5-diiodo-4-pyridone N-acetic acid, expediently in a molecular ratio of 1 : 1 can act on each other, forming a salt-like molecular compound.



   To prepare the molecular compound, for example, 40.5 g of 3,5-diiodo-4-pyridone-N-acetic acid and 8.71 g of morpholine are dissolved in 250 cubic meters of hot ethanol. On cooling, the new compound crystallizes out in an amount of 48 g. The resulting 3,5diiodo-4-pyridon-N-acetic acid morpholine forms colorless, pearlescent platelets that begin to decompose at 145.degree. It dissolves very easily in water with a neutral reaction and should be used as an aqueous, expediently 20 to 60 percent by volume solution for injections.

Claims (1)

PATENTANSPRUCH : Verfahren zur Herstellung einer für die röntgenographische Darstellung der Organe des tierischen und menschlichen Körpers geeigneten Kontrastsubstanz, dadurch gekennzeichnet, dass man Morpholin und 3, 5-Dijod 4-pyridon-N-essigsäure aufeinander einwirken lässt, wobei sich eine salzartige Molekülver- bindung bildet. PATENT CLAIM: Process for the production of a contrast substance suitable for the X-ray representation of the organs of the animal and human body, characterized in that morpholine and 3,5-diiodo-4-pyridone-N-acetic acid are allowed to act on one another, forming a salt-like molecular compound. Das so erhaltene 3, 5-dijod-4-pyridon-N essigsaure Morpholin bildet farblose, perlmut terglänzende Plättchen, die sich bei 145 C zu zersetzen beginnen. Es ist in Wasser sehr leicht mit neutraler Reaktion löslich und soll als wässerige Losung zu Injektionen verwendet werden. The 3, 5-diiodo-4-pyridone-N acetic acid morpholine thus obtained forms colorless, pearlescent platelets that begin to decompose at 145 C. It is very easily soluble in water with a neutral reaction and is intended to be used as an aqueous solution for injections. UNTERANSPRUCH : Verfahren nach Patentanspruch, dadurch gekennzeichnet, dass man die beiden Aus gangsstoffe im molekularen Verhältnis 1 : 1 aufeinander einwirken lässt. SUBClaim: Process according to claim, characterized in that the two starting materials are allowed to act on one another in a molecular ratio of 1: 1.
CH239111D 1943-10-13 1943-10-13 Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body. CH239111A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH239111T 1943-10-13

Publications (1)

Publication Number Publication Date
CH239111A true CH239111A (en) 1945-09-15

Family

ID=4461025

Family Applications (1)

Application Number Title Priority Date Filing Date
CH239111D CH239111A (en) 1943-10-13 1943-10-13 Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body.

Country Status (1)

Country Link
CH (1) CH239111A (en)

Similar Documents

Publication Publication Date Title
CH239111A (en) Process for the production of a contrast substance suitable for the radiographic representation of the organs of the animal and human body.
DE633786C (en) Process for the preparation of complex compounds of 1,3-dimethylxanthine
AT157575B (en) Process for the production of undecomposed, sterilizable drug solutions from the double compound theophylline-piperazine.
DE601268C (en) Process for the production of durable solutions of glyceric acid calcium suitable for injection
DE617153C (en) Process for the production of water-soluble silver salts of glycerol phosphoric acids
DE937373C (en) Process for the production of aqueous pharmaceutical solutions
DE894560C (en) Process for the preparation of a salt of 4-aminobenzenesulfonylaminomethanesulfonic acid which is readily soluble in water
AT77319B (en) Process for the preparation of water-soluble compounds of cystine and its derivatives with disinfectants for combating typhoid and other infectious diseases which have their origin in the liver.
DE377367C (en) Disinfectants
DE706673C (en) Process for the production of durable, sterilizable injection solutions from salts of 2,6-diiodo-p-phenolsulfonic acid
AT87644B (en) Process for the preparation of compounds of yohimbine containing arsenic.
DE915851C (en) Process for the preparation of solutions containing tyrothricin and streptomycin or dihydrostreptomycin
AT67783B (en) Process for the production of water-soluble silver-protein compounds.
DE2309263C2 (en) Infusion concentrate containing 5,5-diphenylhydantoin sodium
DE442853C (en) Method for producing a preparation that is insoluble in body fluids and emits μ-rays
AT114598B (en) Process for the production of antiseptic agents.
AT128587B (en) Radiological procedure.
AT129598B (en) Process for the production of solutions of basic quinine which can be used in therapy.
DE468171C (en) Process for preparing silver salt photographic emulsions
DE624564C (en) Process for the production of a water-soluble silver salt of acetylsalicylic acid
DE458837C (en) Process for the preparation of an aqueous solution of hexamethylenetetramine silver nitrate suitable for injections
DE539101C (en) Process for the preparation of compounds of agaricic acid
AT98249B (en) Process for the preparation of therapeutically useful solutions of mercury derivatives of oxybenzoic sulfonic acids and their homologues.
DE519531C (en) Process for the production of an easily water-soluble, colloidal silver-tannin-protein compound
AT98253B (en) Process for obtaining durable vaccines from bacteria.